What was the primary outcome of the RE-LY trial?
The primary outcome of the RE-LY trial was stroke or systemic embolism during the mean 2-year follow-up. This outcome occurred at a rate of 1.7%/y in the warfarin (INR, 2 to 3) group compared with 1.11%/y in the 150 mg dabigatran group (RR=0.66 versus warfarin; 95% CI, 0.53 0.82; P<0.001 for superiority).